Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 50

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia

Weeks, Lachelle D., Marinac, Catherine R., Redd, Robert, Abel, Gregory, Lin, Amy, Agrawal, Mridul, Stone, Richard M., Schrag, Deborah, Ebert, Benjamin L.·2022·Blood
DOI 10.1182/blood.2021014418PMC PMC8874362
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2021014418

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Prevalence of diseases of inflammaging. The prevalence of diseases of inflammaging in months −60 through −6 before diagnosis or at the pseudodiagnosis date was determined for patients with MDS/CMML, invasive solid tumor, or a representative Medicare population. Forest plots show ORs for prevalent diseases of inflammaging. (A) MDS/CMML vs representative Medicare by disease group. (B) MDS/CMML vs representative Medicare by individual diagnosis. (C) MDS/CMML vs solid tumor by disease group. Number of patients, prevalence (%), and OR (95%CI) are presented at the right of the forest plot. (D) MDS/CMML vs solid malignancy by individual diagnosis. Cardiovascular disease includes atherosclerotic heart disease, myocardial infarction (MI), cerebrovascular accident (CVA), and cardiomyopathy (heart failure); pulmonary disease includes chronic obstructive pulmonary disease (COPD), asthma, and chronic bronchitis; bone and joint diseases include a combination of osteopenia, osteoporosis, osteoarthritis, rheumatoid arthritis (RA), and gout; metabolic diseases include type 2 diabetes mellitus (T2DM), insulin resistance, fatty liver, and chronic kidney disease (CKD); and neurologic diseases include Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), age-related macular degeneration, and non-Alzheimer dementias (other dementias). Numerical values for the ORs and 95% CIs for individual diagnoses are provided in supplemental Table 1.
Figure 1. Prevalence of diseases of inflammaging. The prevalence of diseases of inflammaging in months −60 through −6 before diagnosis or at the pseudodiagnosis date was determined for patients with MDS/CMML, invasive solid tumor, or a representative Medicare population. Forest plots show ORs for prevalent diseases of inflammaging. (A) MDS/CMML vs representative Medicare by disease group. (B) MDS/CMML vs representative Medicare by individual diagnosis. (C) MDS/CMML vs solid tumor by disease group. Number of patients, prevalence (%), and OR (95%CI) are presented at the right of the forest plot. (D) MDS/CMML vs solid malignancy by individual diagnosis. Cardiovascular disease includes atherosclerotic heart disease, myocardial infarction (MI), cerebrovascular accident (CVA), and cardiomyopathy (heart failure); pulmonary disease includes chronic obstructive pulmonary disease (COPD), asthma, and chronic bronchitis; bone and joint diseases include a combination of osteopenia, osteoporosis, osteoarthritis, rheumatoid arthritis (RA), and gout; metabolic diseases include type 2 diabetes mellitus (T2DM), insulin resistance, fatty liver, and chronic kidney disease (CKD); and neurologic diseases include Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), age-related macular degeneration, and non-Alzheimer dementias (other dementias). Numerical values for the ORs and 95% CIs for individual diagnoses are provided in supplemental Table 1.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 19

  1. Steensma, 2015, Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood., 126, 9, 10.1182/blood-2015-03-631747 · DOI · Paper page
  2. Desai, 2018, Somatic mutations precede acute myeloid leukemia years before diagnosis, Nat Med., 24, 1015, 10.1038/s41591-018-0081-z · DOI · Paper page
  3. Jaiswal, 2014, Age-related clonal hematopoiesis associated with adverse outcomes, N Engl J Med., 371, 2488, 10.1056/NEJMoa1408617 · DOI · Paper page
  4. Sano, 2018, Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 inflammasome, J Am Coll Cardiol., 71, 875, 10.1016/j.jacc.2017.12.037 · DOI · Paper page
  5. Brunner, 2017, Risk and timing of cardiovascular death among patients with myelodysplastic syndromes, Blood Adv., 1, 2032, 10.1182/bloodadvances.2017010165 · DOI · Paper page
  6. Adrianzen Herrera, 2020, Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: A SEER-medicare analysis, Leukemia., 34, 1689, 10.1038/s41375-019-0673-8 · DOI
  7. Kristinsson, 2011, Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes, J Clin Oncol., 29, 2897, 10.1200/JCO.2011.34.8540 · DOI · Paper page
  8. Saif, 2002, Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia, Leuk Lymphoma., 43, 2083, 10.1080/1042819021000016186 · DOI
  9. Basiorka, 2016, The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype, Blood., 128, 2960, 10.1182/blood-2016-07-730556 · DOI · Paper page
  10. Liberale, 2020, Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease, Eur Heart J., 41, 2974, 10.1093/eurheartj/ehz961 · DOI
  11. Vaz Fragoso, 2012, Respiratory impairment and the aging lung: a novel paradigm for assessing pulmonary function, J Gerontol A Biol Sci Med Sci., 67, 264, 10.1093/gerona/glr198 · DOI
  12. Stahl, 2018, Macrophages in the aging liver and age-related liver disease, Front Immunol., 9, 2795, 10.3389/fimmu.2018.02795 · DOI · Paper page
  13. Rezuș, 2019, The link between inflammaging and degenerative joint diseases, Int J Mol Sci., 20, 614, 10.3390/ijms20030614 · DOI
  14. Mészáros, 2020, Neurovascular inflammaging in health and disease, Cells., 9, 1614, 10.3390/cells9071614 · DOI
  15. Dawoud, 2021, Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease [published online ahead of print 19 August 2021], Leukemia., 10.1038/s441375-021-01382-3 · DOI
  16. Weidner, 2017, Myelodysplastic syndromes and bone loss in mice and men, Leukemia., 31, 1003, 10.1038/leu.2017.7 · DOI
  17. Libby, 2018, CHIP (Clonal Hematopoiesis of Indeterminate Potential): potent and newly recognized contributor to cardiovascular risk, Circulation., 138, 666, 10.1161/CIRCULATIONAHA.118.034392 · DOI
  18. Hayden, 2020, Clonal hematopoiesis of indeterminate potential and the risk of mild cognitive impairment or probable dementia in the Women’s Health Initiative Memory Study, Alzheimers Dement., 16, e039121, 10.1002/alz.039121 · DOI
  19. Zaghi, 2009, Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy, Acta Neuropathol., 117, 111, 10.1007/s00401-008-0481-0 · DOI

Cited by

Metadata

Authors
Weeks, L. D., Marinac, C. R., Redd, R., Abel, G., Lin, A., Agrawal, M., Stone, R. M., Schrag, D., & Ebert, B. L.
Affiliations
  • Department of Medical Oncology,
  • Center for Prevention of Progression,
  • Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA;
  • Division of Population Sciences, Department of Medical Oncology,
ORCID
Venue
Blood
Publisher
American Society of Hematology
Published
2022-02-24
Volume
139
Issue
8
Pages
1246-1250
ISSN
  • 0006-4971
  • 1528-0020
DOI
10.1182/blood.2021014418
PMC
PMC8874362
Cited by
50
References
8
Language
en
Licence
creativecommons.org/licenses/by-nc-nd/4.0/legalcode (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review